{"filing":{"accession_number":"0001837607-26-000052","cik":"0001837607","ticker":"AEON","company_name":"AEON Biopharma, Inc.","form":"8-K","filing_date":"2026-07-15","report_date":null,"primary_document":"aeon-20260713x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000052/aeon-20260713x8k.htm"},"events":[{"id":18118,"run_id":16272,"accession_number":"0001837607-26-000052","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"AEON Biopharma completed a registered public offering on July 15, 2026, issuing 17,851,599 shares of common stock and 24,837,008 pre-funded warrants with accompanying milestone warrants, raising approximately $12.2 million in net proceeds. The offering represents a substantial dilutive equity issuance to existing shareholders.","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-07-15","form":"8-K","submitted_at":null,"items":[{"id":16829,"accession_number":"0001837607-26-000052","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma entered into an underwriting agreement on July 13, 2026, for a public offering of 17,851,599 shares of common stock and 24,837,008 pre-funded warrants, with accompanying two-year and five-year milestone warrants. The offering closed on July 15, 2026, raising approximately $12.2 million in net proceeds. This is a registered public offering of equity securities that is materially dilutive to existing shareholders and represents a significant capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:03:56.451352+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16830,"accession_number":"0001837607-26-000052","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma announced pricing of a $13.75 million underwritten public offering of 42,688,606 shares of common stock (or pre-funded warrants) with accompanying milestone warrants, representing a substantial dilutive equity issuance. The press release explicitly discloses the offering size, share count, pricing, and warrant structures, with potential for up to $43.3 million in total gross proceeds including warrant exercises. This is a classic registered public offering of equity securities that will dilute existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:03:56.451352+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16829,"accession_number":"0001837607-26-000052","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma entered into an underwriting agreement on July 13, 2026, for a public offering of 17,851,599 shares of common stock and 24,837,008 pre-funded warrants, with accompanying two-year and five-year milestone warrants. The offering closed on July 15, 2026, raising approximately $12.2 million in net proceeds. This is a registered public offering of equity securities that is materially dilutive to existing shareholders and represents a significant capital raise for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:03:56.451352+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-07-15"},{"id":16830,"accession_number":"0001837607-26-000052","item_number":"8.01","item_title":"Other Events.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma announced pricing of a $13.75 million underwritten public offering of 42,688,606 shares of common stock (or pre-funded warrants) with accompanying milestone warrants, representing a substantial dilutive equity issuance. The press release explicitly discloses the offering size, share count, pricing, and warrant structures, with potential for up to $43.3 million in total gross proceeds including warrant exercises. This is a classic registered public offering of equity securities that will dilute existing shareholders.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-15T20:03:56.451352+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-07-15"}]}